Cristal Therapeutics is a clinical stage company developing nanomedicines for the treatment of cancer and other diseases. The Company’s product candidates are based on its proprietary CriPec® polymeric platform, which enables the design of customised nanomedicines. CriPec®-based products have the potential to provide enhanced efficacy and reduced side effect profiles over current treatment options available in the clinic. The lead product, CriPec® docetaxel, is in clinical phase 1b studies for the treatment of solid tumours, while several other products are in preclinical development.
Cristal Therapeutics was founded in April 2011, as a spin-off of the Department of Pharmaceutics of Utrecht University by Cristianne Rijcken, PharmD PhD and Joost Holthuis PhD.